External broker reports(aggregated public sources), CMB International

CMB International

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>2Q25 was a slight miss (but the market has been cautious since Jun 2025), and we are also cautious about 2H25E.</li><li>However, because Xtep’s FY25E guidance has been conservative and its inventory level has been low and healthy, we tend to believe its sales growth, inventory and discount condition could at least sustain into 2H25E.</li><li>Hence, given its undemanding valuation, we maintain BUY with TP of HK$ 7.20, based on 14x FY25E P/E. The stock is now trading at 10x.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

2Q25 was a slight miss (but the market has been cautious since Jun 2025), and we are also cautious about 2H25E.However, because Xtep’s FY25E guidance has been conservative and its inventory level has been low and healthy, we tend to believe its sales growth, inventory and discount condition could at least sustain into 2H25E.Hence, given its undemanding valuation, we maintain BUY with TP of HK$ 7.20, based on 14x FY25E P/E. The stock is now trading at 10x.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Xtep (1368 HK) - 2Q25 Was Weak but Guidance Remained Intact

Xtep International

Xtep (1368 HK) - 2Q25 Was Weak but Guidance Remained Intact